Download - WHOCC

More documents

Recommendations

Info

QP ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS QP51 ANTIPROTOZOALS A Agents against protozoal diseases Optional classification, see comment on QP51 B Agents against coccidiosis C Agents against amoebosis and histomonosis D Agents against leishmaniosis and trypanosomosis E Agents against babesiosis and theileriosis X Other antiprotozoal agents QP52 ANTHELMINTICS A Anthelmintics Optional classification, see comment on QP52 B Agents against trematodosis C Agents against nematodosis D Agents against cestodosis X Other anthelmintic agents QP53 QP54 ECTOPARASITICIDES, INSECTICIDES AND REPELLENTS A Ectoparasiticides for topical use, incl. insecticides B Ectoparasiticides for systemic use G Repellents ENDECTOCIDES A Macrolytic lactones 153
QP ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS Group QP comprises antiparasitic preparations, including antiprotozoals, insecticides and repellants for local and systemic use. Substances are classified according to a chemical subdivision and may be used for several indications. A special ATCvet classification has been established for the group QP. The ATCvet classification for group QP does not correspond to the classification for group P in the ATC system. Optional subgroups should be used on a national basis for special purposes, for example if some indication is very important nationally. For further information, see QP51, QP52 and QP53. Combinations of endectocides and other parasiticides are classified in QP54 - Endectocides. QP51 ANTIPROTOZOALS In the ATCvet system all antiprotozoal agents are classified in group QP51A. If a therapeutic subdivision of antiprotozoal agents is desired, it can be achieved by using the optional 3rd level subgroups QP51B, QP51C, QP51D and QP51E and using the same chemical subdivision at the 4th and 5th levels as is used in QP51A. Optional classification to QP51A: QP51B - Agents against coccidiosis QP51C - Agents against amoebosis and histomonosis QP51D - Agents against leishmaniosis and trypanosomosis QP51E - Agents against babesiosis and theileriosis QP51X - Other antiprotozoal agents Optional subgroups should be used on a national basis for special purposes, for example if a particular indication is very important nationally. When the ATCvet system is used for sales statistics purposes, it has to be remembered that one product must have only one ATCvet code. For such purposes, the ATCvet code for the main indication should be chosen. QP51A AGENTS AGAINST PROTOZOAL DISEASES The group is subdivided at the 4th level according to chemical structure. QP51AA Nitroimidazole derivatives 154
Page 2 and 3:
Guidelines for ATCvet classificatio
Page 4 and 5:
Guidelines for ATCvet classificatio
Page 6 and 7:
Preface The Anatomical Therapeutic
Page 8 and 9:
Contents 1 Introduction to the ATCv
Page 10:
QN - Nervous system................
Page 13 and 14:
1.3 Relationship between the ATCvet
Page 15 and 16:
Classification according to the mai
Page 17 and 18:
2.2 Classification of plain prepara
Page 19 and 20:
- Proposed ATCvet classification, w
Page 22 and 23:
QA ALIMENTARY TRACT AND METABOLISM
Page 24 and 25:
QA ALIMENTARY TRACT AND METABOLISM
Page 26 and 27:
QA02B DRUGS FOR PEPTIC ULCER AND GA
Page 28 and 29:
QA03D QA03DA QA03DB QA03DC ANTISPAS
Page 30 and 31:
Combined packages comprising tablet
Page 32 and 33:
QA07D QA07DA ANTIPROPULSIVES Antipr
Page 34 and 35:
QA10BD QA10BF QA10BG QA10BH QA10BX
Page 36 and 37:
QA11GB Ascorbic acid (vitamin C), c
Page 38 and 39:
QA12CD QA12CE Fluoride Selenium Sod
Page 40 and 41:
QB BLOOD AND BLOOD FORMING ORGANS Q
Page 42 and 43:
QB02BC Local hemostatics Gauze, tam
Page 44 and 45:
QB05C IRRIGATING SOLUTIONS Preparat
Page 46 and 47:
QC CARDIOVASCULAR SYSTEM QC01 QC02
Page 48 and 49:
QC CARDIOVASCULAR SYSTEM QC01 QC01A
Page 50 and 51:
QC01D VASODILATORS USED IN CARDIAC
Page 52 and 53:
QC02DC QC02DD QC02DG QC02K Pyrimidi
Page 54 and 55:
QC03C HIGH-CEILING DIURETICS High-c
Page 56 and 57:
QC05C QC05CA QC05CX CAPILLARY STABI
Page 58 and 59:
QC08D QC08DA QC08DB SELECTIVE CALCI
Page 60 and 61:
QD DERMATOLOGICALS QD01 QD02 QD03 Q
Page 62 and 63:
QD DERMATOLOGICALS This main group
Page 64 and 65:
QD02BB Protectives against UV-radia
Page 66 and 67:
QD05BX Other drugs for keratoseborr
Page 68 and 69:
QD07C CORTICOSTEROIDS, COMBINATIONS
Page 70 and 71:
QD08AH Quinoline derivatives Chloro
Page 72 and 73:
QG GENITO URINARY SYSTEM AND SEX HO
Page 74 and 75:
QG01AA Antibiotics Combinations wit
Page 76 and 77:
QG02CB QG02CC Prolactine inhibitors
Page 78 and 79:
The group is subdivided according t
Page 80 and 81:
QG04B OTHER UROLOGICALS, INCL. ANTI
Page 82:
QG52 PRODUCTS FOR TEATS AND UDDER P
Page 85 and 86:
QH SYSTEMIC HORMONAL PREPARATIONS,
Page 87 and 88:
QH02 CORTICOSTEROIDS FOR SYSTEMIC U
Page 89 and 90:
QH05B QH05BA ANTI-PARATHYROID AGENT
Page 91 and 92:
QI09 QI10 QI11 Q120 IMMUNOLOGICALS
Page 93 and 94:
QI01 QI01A QI01AA QI01AB QI01AC QI0
Page 95 and 96:
QI01C QI01CA QI01CB QI01CC QI01CD Q
Page 97 and 98:
QI01E QI01EA QI01EB QI01EC QI01ED Q
Page 99 and 100:
QI01KV QI01KX Other inactivated vac
Page 101 and 102:
QI03AM QI03AN QI03AO QI03AP QI03AQ
Page 103 and 104: QI05AH QI05AI QI05AJ Live and inact
Page 105 and 106: QI07 QI07A QI07AA QI07AB QI07AC QI0
Page 107 and 108: QI07X QI07XA QI07XB QI07XC QI07XD Q
Page 109 and 110: QI08B HARE QI08X LEPORIDAE, OTHERS
Page 111 and 112: QI10AR QI10AS QI10AU QI10AV QI10AX
Page 113 and 114: QI20AD QI20AE QI20AF QI20AG QI20AH
Page 115 and 116: QI20DD QI20DE QI20DF QI20DG QI20DH
Page 117 and 118: QJ ANTIINFECTIVES FOR SYSTEMIC USE
Page 119 and 120: QJ01D OTHER BETA-LACTAM ANTIBACTERI
Page 121 and 122: QJ01FG Streptogramins The streptogr
Page 123 and 124: QJ01XX Other antibacterials Fumagil
Page 125 and 126: QJ05AH Neuraminidase inhibitors All
Page 127 and 128: QJ51RB QJ51RC QJ51RD Amphenicols, c
Page 129 and 130: QL ANTINEOPLASTIC AND IMMUNOMODULAT
Page 131 and 132: QL02 ENDOCRINE THERAPY Only prepara
Page 134 and 135: QM MUSCULO-SKELETAL SYSTEM QM01 QM0
Page 136 and 137: QM01B QM01BA ANTIINFLAMMATORY/ANTIR
Page 138 and 139: QM03BC Ethers, chemically close to
Page 140 and 141: QN NERVOUS SYSTEM QN01 QN02 QN03 QN
Page 142 and 143: QN01B ANESTHETICS, LOCAL Local anes
Page 144 and 145: QN02AG Opioids in combination with
Page 146 and 147: QN03AF QN03AG QN03AX Carboxamide de
Page 148 and 149: QN05B ANXIOLYTICS Preparations used
Page 150 and 151: Lithium, see QN05AN - Lithium. Comb
Page 152: QN07C QN07CA ANTIVERTIGO PREPARATIO
Page 157 and 158: Optional subgroups should be used o
Page 159 and 160: QP53BB Organophosphorous compounds
Page 161 and 162: QR RESPIRATORY SYSTEM Preparations
Page 163 and 164: QR03 QR03A DRUGS FOR OBSTRUCTIVE AI
Page 165 and 166: Preparations which contain small am
Page 167 and 168: QR06AE Piperazine derivatives Cinna
Page 169 and 170: QS SENSORY ORGANS Preparations for
Page 171 and 172: QS01E ANTIGLAUCOMA PREPARATIONS AND
Page 173 and 174: QS01KA Viscoelastic substances Hyal
Page 175 and 176: QS03 OPHTHALMOLOGICAL AND OTOLOGICA
Page 177 and 178: QV VARIOUS This group is the most h
Page 179 and 180: QV04CC Tests for bile duct patency
Page 181 and 182: QV07AC Blood transfusion, auxiliary
Page 183 and 184: QV09A CENTRAL NERVOUS SYSTEM This g
Page 185 and 186: QV09G CARDIOVASCULAR SYSTEM This gr
Page 187 and 188: QV10X OTHER THERAPEUTIC RADIOPHARMA
Page 190 and 191: WHO COLLABORATING CENTRE FOR DRUG S
Page 192: ANNEX II
Page 195: ORDER FORM - ATCvet PUBLICATIONS Pa
show all

Download - WHOCC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?